<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Horisberger A</submitter><funding>NCATS NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIAMS NIH HHS</funding><pagination>e181034</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12352894</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>135(16)</volume><pubmed_abstract>Lupus nephritis (LN) is a frequent manifestation of systemic lupus erythematosus, and fewer than half of patients achieve complete renal response with standard immunosuppressants. Identifying noninvasive, blood-based immune alterations associated with renal injury could aid therapeutic decisions. Here, we used mass cytometry immunophenotyping of peripheral blood mononuclear cells in 145 patients with biopsy-proven LN and 40 healthy controls to evaluate the heterogeneity of immune activation and identify correlates of renal parameters. Unbiased analysis identified 3 immunologically distinct groups of patients that were associated with different patterns of histopathology, renal cell infiltrates, urine proteomic profiles, and treatment response at 1 year. Patients with enriched circulating g</pubmed_abstract><journal>The Journal of clinical investigation</journal><pubmed_title>Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis.</pubmed_title><pmcid>PMC12352894</pmcid><funding_grant_id>UH2 AR067689</funding_grant_id><funding_grant_id>UH2 AR067679</funding_grant_id><funding_grant_id>UL1 TR002541</funding_grant_id><funding_grant_id>UH2-AR067691</funding_grant_id><funding_grant_id>UH2 AR067694</funding_grant_id><funding_grant_id>UH2-AR067681</funding_grant_id><funding_grant_id>UH2 AR067681</funding_grant_id><funding_grant_id>and UM2- AR067678</funding_grant_id><funding_grant_id>UH2-AR067694</funding_grant_id><funding_grant_id>UH2 AR067676</funding_grant_id><funding_grant_id>UH2 AR067688</funding_grant_id><funding_grant_id>UH2 AR067677</funding_grant_id><funding_grant_id>UH2 AR067685</funding_grant_id><funding_grant_id>UH2-AR067690</funding_grant_id><funding_grant_id>UM2 AR067678</funding_grant_id><funding_grant_id>UH2-AR067677</funding_grant_id><funding_grant_id>UH2-AR067688</funding_grant_id><funding_grant_id>UH2-AR067689</funding_grant_id><funding_grant_id>UH2-AR067679</funding_grant_id><funding_grant_id>UH2 AR067690</funding_grant_id><funding_grant_id>UH2 AR067691</funding_grant_id><funding_grant_id>UH2-AR067685</funding_grant_id><funding_grant_id>UH2-AR067676</funding_grant_id><pubmed_authors>Pulford J</pubmed_authors><pubmed_authors>Zhang F</pubmed_authors><pubmed_authors>Wofsy D</pubmed_authors><pubmed_authors>Davidson A</pubmed_authors><pubmed_authors>Raychaudhuri S</pubmed_authors><pubmed_authors>Guthridge J</pubmed_authors><pubmed_authors>Buyon JP</pubmed_authors><pubmed_authors>Hancock B</pubmed_authors><pubmed_authors>Payan-Schober F</pubmed_authors><pubmed_authors>Gutierrez-Arcelus M</pubmed_authors><pubmed_authors>Weisman M</pubmed_authors><pubmed_authors>Eisenhaure TM</pubmed_authors><pubmed_authors>Furie R</pubmed_authors><pubmed_authors>Berthier CC</pubmed_authors><pubmed_authors>Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network</pubmed_authors><pubmed_authors>James JA</pubmed_authors><pubmed_authors>Dall'Era M</pubmed_authors><pubmed_authors>Kalunian KC</pubmed_authors><pubmed_authors>Grossman J</pubmed_authors><pubmed_authors>Keegan J</pubmed_authors><pubmed_authors>Kretzler M</pubmed_authors><pubmed_authors>Brenner MB</pubmed_authors><pubmed_authors>Hacohen N</pubmed_authors><pubmed_authors>Ishimori M</pubmed_authors><pubmed_authors>Griffith A</pubmed_authors><pubmed_authors>McMahon MA</pubmed_authors><pubmed_authors>Diamond B</pubmed_authors><pubmed_authors>Barnas JL</pubmed_authors><pubmed_authors>Sasaki T</pubmed_authors><pubmed_authors>Howard K</pubmed_authors><pubmed_authors>Demeke DS</pubmed_authors><pubmed_authors>Clancy R</pubmed_authors><pubmed_authors>Arazi A</pubmed_authors><pubmed_authors>Belmont M</pubmed_authors><pubmed_authors>Lederer JA</pubmed_authors><pubmed_authors>Horisberger A</pubmed_authors><pubmed_authors>Apruzzese W</pubmed_authors><pubmed_authors>Preisinger K</pubmed_authors><pubmed_authors>Beuschel R</pubmed_authors><pubmed_authors>Izmirly P</pubmed_authors><pubmed_authors>Petri MA</pubmed_authors><pubmed_authors>Fava A</pubmed_authors><pubmed_authors>Hodgin JB</pubmed_authors><pubmed_authors>Rao DA</pubmed_authors><pubmed_authors>Hoover PJ</pubmed_authors><pubmed_authors>Anolik JH</pubmed_authors><pubmed_authors>Inamo J</pubmed_authors><pubmed_authors>Ghosh T</pubmed_authors><pubmed_authors>Woodle ES</pubmed_authors><pubmed_authors>Putterman C</pubmed_authors><pubmed_authors>Cao Y</pubmed_authors><pubmed_authors>Hildeman D</pubmed_authors><pubmed_authors>Murzin E</pubmed_authors><pubmed_authors>Kamen DL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis.</name><description>Lupus nephritis (LN) is a frequent manifestation of systemic lupus erythematosus, and fewer than half of patients achieve complete renal response with standard immunosuppressants. Identifying noninvasive, blood-based immune alterations associated with renal injury could aid therapeutic decisions. Here, we used mass cytometry immunophenotyping of peripheral blood mononuclear cells in 145 patients with biopsy-proven LN and 40 healthy controls to evaluate the heterogeneity of immune activation and identify correlates of renal parameters. Unbiased analysis identified 3 immunologically distinct groups of patients that were associated with different patterns of histopathology, renal cell infiltrates, urine proteomic profiles, and treatment response at 1 year. Patients with enriched circulating g</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-05-29T15:28:44.456Z</modification><creation>2026-04-08T05:20:15.866Z</creation></dates><accession>S-EPMC12352894</accession><cross_references><pubmed>40536813</pubmed><doi>10.1172/JCI181034</doi></cross_references></HashMap>